Optimal anti-VEGF therapy regimen

We are delighted to announce that we are expanding A Chat with Anat! We will be partnering with the Vision Academy, a group of retinal experts who collaborate to provide guidance to the retinal community. I will be joined by internationally renowned Vision Academy experts to discuss practice-focused topics covering clinical challenges in ophthalmology and controversies in care.

In this episode of A Chat with Anat, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney, and Dr Alex Hunyor, Associate Professor of Ophthalmology at the University of Sydney, discuss pragmatic considerations to reduce the burden of bilateral anti-VEGF injections.

Professor Mitchell and Dr Hunyor explore how bilateral disease significantly impacts patient quality of life, and how bilateral treatment, especially if the eyes are being treated on different days, can lead to significant burden for patients, caregivers, and for their healthcare system.

Their conversation also covers how to explain to patients the need for, and risks of, bilateral injections, and how we, as ophthalmologists, can minimise any potential risks with the treatment procedure.

The Vision Academy viewpoint providing guidance on bilateral injections, and other important viewpoints and resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.

If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their experiences in navigating the importance of addressing anxiety and depression in our patients with nAMD, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.

SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!

Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources

This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
July 2023 MA-PFM-OPHT-ALL-1181-1

This podcast series is intended for HCPs, and is not intended for UK audiences.

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.